Curevac GmbH has landed a $52 million equity investment from the Bill & Melinda Gates Foundation plus an additional $24 million equity investment from longstanding investor Dievini Hopp Biotech to support continued development of its messenger RNA-based vaccines and the construction of a new manufacturing facility that will allow it to vastly scale up its capacity to produce commercial quantities of vaccines.